Multiple myeloma in Latin America: Are we moving at the same pace as other regions?
DOI:
https://doi.org/10.35509/01239015.986Resumen
Multiple myeloma (MM) is a plasma cell disorder that has recently experienced a dramatic improvement in clinical outcomes mainly due to the advent of novel drugs and the implementation of better supportive care strategies (1). Recently available combinations of proteasome inhibitors (PIs), immunomodulators (IMiDs), and monoclonal antibodies like daratumumab and isatuximab are shifting the MM therapeutic landscape (2-4). Nonetheless, MM still remains incurable, with an estimated 5-year survival of 55% and an estimated death rate of 2% in 2021 (% of all cancer deaths) (5).
In Latin America (LATAM), the Hemato-Oncology Latin America (HOLA) study was recently designed to evaluate the epidemiology of hematologic malignancies in the real-world setting (6). In some countries from LATAM, stage III MM was the most frequently observed disease stage, with Mexico (62.5%), Chile (60.0%), Brazil (49.3%), and Colombia (45.8%) being the regions where MM patients presented with a more advanced stage. This is in contrast with the original report of revised staging criteria, where stage III MM represented 22% of the cases (7). In the entire cohort of the HOLA study, 497 patients with MM (32.7%) underwent autologous stem-cell transplantation (ASCT); however, the proportion of patients submitted to ASCT varied among countries, ranging from 3% to 69%. The 497 patients who underwent ASCT had received induction chemotherapy predominantly based on thalidomide (151; 30.4%) and bortezomib (125; 25.2%) regimens. This is quite different when compared to countries like Canada, where in a recent study by Mian et al. (8), a total of 5,154 patients with MM were identified, among which 3,030 patients (58.8%) received an upfront ASCT and 2,124 (41.2%) did not. Bortezomib and lenalidomide were the most frequently used agents (>50%) in first- and second-line treatment, respectively, in both the ASCT and non-ASCT cohorts. In Colombia, Abello et al. (9) reported on the outcomes of 890 patients with MM from a real-world registry. Most patients in this group received bortezomib and thalidomide-based therapies with a 65% response rate for CyBorD (cyclophosphamide, bortezomib, and dexamethasone) and 79% for VTD (bortezomib, thalidomide, and dexamethasone), which is in contrast with 78.1-84.3% and 85-94% reported in other series treated with similar regimens (10-12).
Biografía del autor/a
Victor H Jimenez-Zepeda, Tom Baker Cancer Centre, Alberta Health Services, Calgary, Canada.
1. Tom Baker Cancer Centre, Alberta Health Services, Calgary, Canada.
2. Cumming School of Medicine, University of Calgary, Calgary, Canada.
3. Arnie Charbonneu Cancer Research Institute, Calgary, Canada.
Referencias bibliográficas
Jimenez-Zepeda VH, Chen G, Shaw E, Farris MS, Cowling T, Tay J. Real-world treatment patterns for patients with newly diagnosed multiple myeloma in Alberta, Canada. Leuk Lymphoma. 2022;63(11):2557-64. https://doi.org/10.1080/10428194.2022.2092852
Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, et al. Overall survival with daratumumab, lenalidomide, and dexamethasone in previously treated multiple myeloma (POLLUX): A randomized, open-label, phase III trial. J Clin Oncol. 2023;41(8):1590-99. https://doi.org/10.1200/JCO.22.00940
Richardson PG, Beksaç M, Špička I, Mikhael J. Isatuximab for the treatment of relapsed/refractory multiple myeloma. Expert Opin Biol Ther. 2020;20(12):1395-404. https://doi.org/10.1080/14712598.2021.1841747
Davies F, Rifkin R, Costello C, Morgan G, Usmani S, Abonour R, et al. Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US. Ann Hematol. 2021;100(9):2325-37. https://doi.org/10.1007/s00277-021-04534-8
National Cancer Institute. Cancer Stat Facts: Myeloma. Accessed July 14, 2021. Available from: https://seer.cancer.gov/statfacts/html/mulmy.html
Tietsche de Moraes Hungria V, Chiattone C, Pavlovsky M, Abenoza LM, Agreda GP, Armenta J, et al. Epidemiology of hematologic malignancies in real-world settings: findings from the Hemato-Oncology Latin America observational registry study. J Glob Oncol. 2019;5:1-19. https://doi.org/10.1200/JGO.19.00025
Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised international staging system for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol. 2015;33(26):2863-9. https://doi.org/10.1200/JCO.2015.61.2267
Mian H, Reece D, Masih-Khan E, McCurdy A, Kardjadj M, Jimenez-Zepeda VH, et al. Survival and outcomes of newly diagnosed multiple myeloma patients stratified by transplant status 2007-2018: retrospective analysis from the Canadian Myeloma Research Group Database. Clin Lymphoma Myeloma Leuk. 2022;22(8):608-17. https://doi.org/10.1016/j.clml.2022.03.002
Abello V, Mantilla WA, Idrobo H, Sossa CL, Salazar LA, Pena A, et al. Real-world evidence of epidemiology and clinical outcomes in multiple myeloma, findings from the registry of hemato-oncologic malignancies in Colombia, observational study. Clin Lymphoma Myeloma Leuk. 2022;22(6):e405-e413. https://doi.org/10.1016/j.clml.2021.12.009
Moreau P, Hulin C, Macro M, Caillot D, Chaleteix C, Roussel M, et al. VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial. Blood. 2016;127(21):2569-74. https://doi.org/10.1182/blood-2016-01-693580
Rosiñol L, Oriol A, Teruel AI, Hernández D, López-Jiménez J, de la Rubia J, et al. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. Blood. 2012;120(8):1589-96. https://doi.org/10.1182/blood-2012-02-408922
Areethamsirikul N, Masih-Khan E, Chu CM, Jimenez-Zepeda V, Reece DE, Trudel S, et al. CyBorD induction therapy in clinical practice. Bone Marrow Transplant. 2015;50(3):375-9. https://doi.org/10.1038/bmt.2014.288
San-Miguel J, Dhakal B, Yong K, Spencer A, Anguille S, Mateos MV, et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N Engl J Med. 2023 Jun 5. https://doi.org/10.1056/NEJMoa2303379
Rodriguez-Otero P, Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK, et al. Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N Engl J Med. 2023;388(11):1002-14. https://doi.org/10.1056/NEJMoa2213614
Petrou P. CAR-T therapy for multiple myeloma in China. Does it make sense financially? J Med Econ. 2023:1-4. https://doi.org/10.1080/13696998.2023.2224636
Gómez-Almaguer D, de Moraes Hungria VT. Multiple myeloma in Latin America. Hematology. 2022;27(1):928-31. https://doi.org/10.1080/16078454.2022.2112643
Pessoa de Magalhães Filho RJ, Crusoe E, Riva E, Bujan W, Conte G, Navarro JR, et al. Analysis of availability and access of anti-myeloma drugs and impact on the management of multiple myeloma in Latin American countries. Clin Lymphoma Myeloma Leuk. 2019;19(1):e43-e50. https://doi.org/10.1016/j.clml.2018.08.005
Tarín-Arzaga L, Arredondo-Campos D, Martínez-Pacheco V, Martínez-González O, Ramírez-López A, Gómez-De León A, et al. Impact of the affordability of novel agents in patients with multiple myeloma: real-world data of current clinical practice in Mexico. Cancer. 2018;124(9):1946-53. https://doi.org/10.1002/cncr.31305
Peña C, Riva E, Schutz N, Tarín-Arzaga L, Martínez-Cordero H, Bove V, et al. Different outcomes for transplant-eligible newly diagnosed multiple myeloma patients in Latin America according to the public versus private management: a GELAMM study. Leuk Lymphoma. 2020;61(13):3112-19. https://doi.org/10.1080/10428194.2020.1804558
Riva E, Schütz N, Peña C, Ruiz-Argüelles G, Hopkins CR, Bove V, et al. Significant differences in access to tests and treatments for multiple myeloma between public and private systems in Latin America. Results of a Latin American survey. GELAMM (Grupo de Estudio Latino Americano de Mieloma Múltiple). Ann Hematol. 2020;99(5):1025-30. https://doi.org/10.1007/s00277-020-03983-x
Hamerschlak N, de Lima M. Improving patient access to modern myeloma therapy in Latin America: first step, know what your problem really is. Leuk Lymphoma. 2020;61(13):3033-4. https://doi.org/10.1080/10428194.2020.1821013
Cómo citar
Descargas
Descargas
Publicado
Número
Sección
Licencia
Derechos de autor 2023 Revista Colombiana de Cancerología
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.
Todos los derechos reservados.
